1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Community-Acquired Infections – Pipeline Review, H1 2013

Community-Acquired Infections – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 42 pages

Community-Acquired Infections – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Community-Acquired Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Community-Acquired Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Community-Acquired Infections. Community-Acquired Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Community-Acquired Infections.
- A review of the Community-Acquired Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Community-Acquired Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Community-Acquired Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Community-Acquired Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Community-Acquired Infections - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Community-Acquired Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Community-Acquired Infections 7
Community-Acquired Infections Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Community-Acquired Infections Therapeutics - Products under Development by Companies 12
Companies Involved in Community-Acquired Infections Therapeutics Development 13
Paratek Pharmaceuticals, Inc. 13
Dongwha Pharm Co., Ltd. 14
Implicit Bioscience Limited 15
Tetraphase Pharmaceuticals Inc. 16
TaiGen Biotechnology Co., Ltd. 17
Community-Acquired Infections - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
omadacycline tosylate - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
zabofloxacin - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
nemonoxacin - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
avarofloxacin - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
eravacycline - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Community-Acquired Infections Therapeutics - Drug Profile Updates 33
Community-Acquired Infections Therapeutics - Discontinued Products 36
Community-Acquired Infections Therapeutics - Dormant Products 37
Community-Acquired Infections - Product Development Milestones 38
Featured News and Press Releases 38
Sep 05, 2012: Tetraphase Pharma To Present New Clinical And Preclinical Research On Antibiotic Portfolio At ICAAC 2012 38
Apr 13, 2012: Cempra To Present Overview On Solithromycin At Future Leaders In Biotechnology Industry Conference 38
Mar 28, 2012: Paratek Wins Agreement With FDA On Special Protocol Assessment For Phase III Study In Community-Acquired Bacterial Pneumonia 39
Sep 15, 2011: Cempra Announces Comparable Efficacy Of Oral Solithromycin Compared With Levofloxacin In Phase II Clinical Trial In Patients With Community-Acquired Bacterial Pneumonia 39
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42



List of Tables

Number of Products Under Development for Community-Acquired Infections, H1 2013 7
Products under Development for Community-Acquired Infections - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Late Stage Development, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Products under Development by Companies, H1 2013 12
Paratek Pharmaceuticals, Inc., H1 2013 13
Dongwha Pharm Co., Ltd., H1 2013 14
Implicit Bioscience Limited, H1 2013 15
Tetraphase Pharmaceuticals Inc., H1 2013 16
TaiGen Biotechnology Co., Ltd., H1 2013 17
Assessment by Monotherapy Products, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 22
Community-Acquired Infections Therapeutics - Drug Profile Updates 33
Community-Acquired Infections Therapeutics - Discontinued Products 36
Community-Acquired Infections Therapeutics - Dormant Products 37



List of Figures

Number of Products under Development for Community-Acquired Infections, H1 2013 7
Products under Development for Community-Acquired Infections - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Late Stage Products, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Assessment by Monotherapy Products, H1 2013 18
Assessment by Route of Administration, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Molecule Type, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  

    Africa  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.